Sign in
Not yet taking people in ItalyPhase 2

Docetaxel with or without carboplatin for advanced prostate cancer after olaparib

Compares docetaxel with or without carboplatin in prostate cancer that progressed after olaparib.

Key facts

Who runs it
Azienda Provinciale Per I Servizi Sanitari
Where
Alba, Aviano, Foggia, Frattamaggiore, Modena, Novara, Padova, Rome, Rozzano, Turin, and Udine, ItalySee the 11 sites
Registry title
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
Status
Not yet recruiting
Phase
Phase 2
People taking part
157 people, planned
Started
1 Sept 2024
Planned end
1 Sept 2026
Type of study
Interventional
Record updated
18 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with metastatic castration-resistant prostate cancer and a known BRCA mutation whose cancer has grown during olaparib treatment.

Age
18 years or older
Sex
Men only
Disease stage
Metastatic castration-resistant prostate adenocarcinoma, with disease progression while on olaparib; effective castration (testosterone ≤0.50 ng/dL); ECOG performance status below 2
Earlier treatment
Must have had an androgen-receptor signaling inhibitor (ARSI), then olaparib. Must not have had chemotherapy for prostate cancer.
Biomarker or test result
A BRCA mutation found earlier. PSA of at least 2 ng/ml at study entry.

Main reasons for not taking part

  • Prior chemotherapy for prostate cancer
  • History of brain metastases or uncontrolled spinal cord compression
  • Serious heart disease, such as a heart attack within 6 months
  • Another cancer, with a few exceptions such as treated skin cancer
  • Poor bone marrow, liver or kidney function

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Histologically- or cytologically-confirmed prostate adenocarcinoma
  • Performance status ECOG <2
  • Ability to fill the quality of life questionnaire
  • Written informed consent
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Previous detection of BRCA mutation
  • Treatment for mCRPC with an ARSI and subsequent treatment with olaparib
  • Progressive disease while receiving Olaparib documented by: I. Increase in measurable disease (RECIST 1.1), and/or II. Appearance of new lesions, including those on bone scan (≥2 new lesions on 2 consecutive bone scans if progression disease diagnosed on bone scan only) consistent with progressive prostate cancer, and/or III. Rising PSA defined as 2 sequential increases above a previous lowest reference value. Each value must be obtained at least 1 week apart. A PSA value of at least 2 ng/ml is required at study entry. For patients evaluated with PET the progressive disease should be documented by at least one of the following criteria: I. appearance of at least two new lesions, and/or II. Increase of ≥30% of the uptake or of the tumoral volume
  • Effective castration (serum testosterone levels ≤0.50 ng/dL) by orchiectomy and/or LHRH agonists or antagonist with or without anti-androgens
  • Age ≥18 years

Who cannot take part

  • Prior chemotherapy for prostate cancer
  • Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow
  • Contraindications to the use of corticosteroid treatment
  • Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event
  • Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization
  • Any other condition which in the judgment of the investigator would place the subject at undue risk or interfere with the study
  • History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease
  • Inadequate organ and bone marrow function as evidenced by: a. Hemoglobin <10.0 g/dL b. Absolute neutrophil count <1.5 x 109/L, c. Platelet count <100 x 109/L, d. AST and/or ALT >1.5 x ULN; e. Total bilirubin >1.5 x ULN, f. Serum Creatinine >1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated either according to Cockcroft-Gault formula. Creatinine clearance <60 mL/min will exclude the patient
  • Clinically significant cardiovascular disease including the following: a. Myocardial infarction within 6 months before screening; b. Uncontrolled angina within 3 months before screening; c. Congestive heart failure New York Heart Association class 3 or 4, or a history of congestive heart failure New York Heart Association class 3 or 4, unless a screening echocardiogram or multigated acquisition scan performed within 3 months before randomization demonstrates a left ventricular ejection fraction ≥ 50%; d. History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes); e. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place; f. Hypotension as indicated by systolic blood pressure < 86 millimeters of mercury (mm Hg) at screening; g. Bradycardia as indicated by a heart rate of < 45 beats per minute on the screening electrocardiogram (ECG) and on physical examination; h. Uncontrolled hypertension as indicated by systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening
  • Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which chemotherapy has been completed >5 years ago and from which the patient has been disease-free for >5 years
  • Inability to ensure follow-up

Where in Italy

  • Azienda Sanitaria Locale Cn2 Alba-BraAlba, ItalyNot yet recruiting
  • Centro di Riferimento Oncologico di AvianoAviano, ItalyNot yet recruiting
  • Azienda Ospedaliero Universitaria Ospedali RiunitiFoggia, ItalyNot yet recruiting
  • Azienda Sanitaria Locale Napoli 2 NordFrattamaggiore, ItalyNot yet recruiting
  • Azienda Ospedaliero - Universitaria di ModenaModena, ItalyNot yet recruiting
  • Azienda Ospedaliero Universitaria Maggiore della CaritàNovara, ItalyNot yet recruiting
  • Istituto Oncologico VenetoPadova, ItalyNot yet recruiting
  • I.F.O. Istituti Fisioterapici OspitalieriRome, ItalyNot yet recruiting
  • Humanitas Research HospitalRozzano, ItalyNot yet recruiting
  • Azienda Ospedaliera Ordine Mauriziano di TorinoTurin, ItalyNot yet recruiting
  • Azienda Sanitaria Universitaria Friuli CentraleUdine, ItalyNot yet recruiting

About the trial

What the trial wants to find out

To demonstrate the superiority of the combination of docetaxel + prednisone / carboplatin (Arm A) compared to docetaxel + prednisone (Arm B) in patients with mCRPC progressing after one androgen-receptor signaling inhibitor (ARSI) followed by olaparib.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
Plain-language title
Docetaxel with or without carboplatin for advanced prostate cancer after olaparibGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
18 November 2024